| Electrospinning for drug delivery applications: A review A Luraghi, F Peri, L Moroni Journal of Controlled release 334, 463-484, 2021 | 456 | 2021 |
| Phytosterol and γ-oryzanol conjugates: synthesis and evaluation of their antioxidant, antiproliferative, and anticholesterol activities G Lesma, A Luraghi, T Bavaro, R Bortolozzi, G Rainoldi, G Roda, G Viola, ... Journal of natural products 81 (10), 2212-2221, 2018 | 31 | 2018 |
| Ecdysteroid derivatives that reverse P-glycoprotein-mediated drug resistance R Bortolozzi, A Luraghi, E Mattiuzzo, A Sacchetti, A Silvani, G Viola Journal of Natural Products 83 (8), 2434-2446, 2020 | 19 | 2020 |
| Effect of chemical modulation of toll-like receptor 4 in an animal model of ulcerative colitis FA Facchini, D Di Fusco, S Barresi, A Luraghi, A Minotti, F Granucci, ... European Journal of Clinical Pharmacology 76, 409-418, 2020 | 17 | 2020 |
| Synthetic glycolipids as molecular vaccine adjuvants: mechanism of action in human cells and in vivo activity FA Facchini, A Minotti, A Luraghi, A Romerio, N Gotri, A Matamoros-Recio, ... Journal of Medicinal Chemistry 64 (16), 12261-12272, 2021 | 16 | 2021 |
| Istaroxime metabolite PST3093 selectively stimulates SERCA2a and reverses disease-induced changes in cardiac function M Arici, M Ferrandi, P Barassi, SC Hsu, E Torre, A Luraghi, C Ronchi, ... Journal of Pharmacology and Experimental Therapeutics 384 (1), 231-244, 2023 | 15 | 2023 |
| Multicomponent Approach to Bioactive Peptide–Ecdysteroid Conjugates: Creating Diversity at C6 by Means of the Ugi Reaction G Lesma, A Luraghi, G Rainoldi, E Mattiuzzo, R Bortolozzi, G Viola, ... Synthesis 48 (22), 3907-3916, 2016 | 13 | 2016 |
| A Highly Sensitive Luminescent Biosensor for the Microvolumetric Detection of the Pseudomonas aeruginosa Siderophore Pyochelin D Visaggio, M Pirolo, E Frangipani, M Lucidi, R Sorrentino, E Mitidieri, ... ACS sensors 6 (9), 3273-3283, 2021 | 11 | 2021 |
| Highly selective SERCA2a activators: Preclinical development of a congeneric group of first-in-class drug leads against heart failure A Luraghi, M Ferrandi, P Barassi, M Arici, SC Hsu, E Torre, C Ronchi, ... Journal of Medicinal Chemistry 65 (10), 7324-7333, 2022 | 10 | 2022 |
| Selective SERCA2a activator as a candidate for chronic heart failure therapy M Arici, SC Hsu, M Ferrandi, P Barassi, C Ronchi, E Torre, A Luraghi, ... Journal of Translational Medicine 22 (1), 77, 2024 | | 2024 |
| Androstane Derivatives with Activity as Pure or Predominantly Pure Stimulators of SERCA2a for the Treatment of Heart Failure. A Cerri, P Ferrari, M Ferrandi, P Barassi, G Bianchi, HSU Shih-Che, F Peri, ... US Patent App. 17/640,294, 2023 | | 2023 |
| CHARACTERIZING THE EFFECTS OF ISTAROXIME EMBEDDED ELECTROSPUN SCAFFOLDS ON CARDIOMYOCYTES IN VITRO R Sakina, A Llucia-Valldeperas, S Gelsomino, A Luraghi, F Peri, ... TISSUE ENGINEERING PART A 28, S378-S378, 2022 | | 2022 |
| Rational drug design and synthesis of new steroid derivatives for the treatment of chronic heart failure A Luraghi Università degli Studi di Milano-Bicocca, 2021 | | 2021 |
| The long-lasting istaroxime metabolite PST3093 stimulates SERCA2a and reverses disease-induced changes in cardiac function M Arici, M Ferrandi, S Hsu, E Torre, P Barassi, A Luraghi, C Ronchi, ... | | 2021 |
